RxDoctor Payments DataLook up a doctor →

David Badesch, MD

Pulmonary Disease · Aurora, CONPI 1275623951

Payments from drug & device makers

$2,215,419in general payments, 2019–2025

Across 371 payments — averaging $5971.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$1.7M
  • United Therapeutics Corporation$330K
  • Janssen Research & Development, LLC$81K
  • Actelion Pharmaceuticals, Ltd$50K
  • Novartis$31K
  • Pfizer$30K
  • plus $16K from 3 others

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,215,419 in reported general payments places this provider in the 95th percentile of 248 pulmonary disease providers in Colorado.

See all pulmonary disease providers in Colorado

Medicare billing

Part B allowed, 2024
$42,818
Medicare patients
170
Services billed
397

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →